701 LEE ROAD, WAYNE, PA
Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Investor Presentation
Annual Report to Security Holders
Aclaris Therapeutics Raises $20 Million Through Common Stock Sale
Aclaris Therapeutics Sells 12.7 Million Shares for $39.8 Million
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence